Merck KGaA

Product vision
  • Uncomplicated malaria treatment and resistance management
  • Potential for prophylaxis

  • P. falciparum EF2 inhibitor novel mechanism of action

Key features
  • Comparable activity across all stages of the malaria parasite lifecycle 

  • Transmission-blocking activity in a Standard Membrane Feeding Assay

  • First-in-human study and (blood-stage) volunteer infection study completed; volunteer infection study (sporozoite) ongoing
Next milestone
  • Initiate combination study with partner compound
  • Discovery collaboration with the University of Dundee Drug Discovery Unit
  • Names DDD107498; DDD498, MMV121
MMV Project Director
  • Dr Cristina Donini